All Fiber-Optic Immunosensors Based on Elliptical Core Helical Intermediate-Period Fiber Grating with Low-Sensitivity to Environmental Disturbances.

Biosensors (Basel)

Key Laboratory of Optoelectronic Devices and Systems of Ministry of Education/Guangdong Province, College of Physics and Optoelectronic Engineering, Shenzhen University, Shenzhen 518060, China.

Published: February 2022

An all fiber-optic immunosensor based on elliptical core helical intermediate-period fiber grating (E-HIPFG) is proposed for the specific detection of human immunoglobulin G (human IgG). E-HIPFGs are all-fiber transducers that do not include any additional coating materials or fiber architectures, simplifying the fabrication process and promising the stability of the E-HIPFG biosensor. For human IgG recognition, the surface of an E-HIPFG is functionalized by goat anti-human IgG. The functionalized E-HIPFG is tested by human IgG solutions with a concentration range of 10-100 μg/mL and shows a high sensitivity of 0.018 nm/(μg/mL) and a limit of detection (LOD) of 4.7 μg/mL. Notably, the functionalized E-HIPFG biosensor is found to be insensitive to environmental disturbances, with a temperature sensitivity of 2.6 pm/°C, a strain sensitivity of 1.2 pm/με, and a torsion sensitivity of -23.566 nm/(rad/mm). The results demonstrate the considerable properties of the immunosensor, with high resistance to environmental perturbations, indicating significant potential for applications in mobile biosensors and compact devices.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8869875PMC
http://dx.doi.org/10.3390/bios12020099DOI Listing

Publication Analysis

Top Keywords

human igg
12
based elliptical
8
elliptical core
8
core helical
8
helical intermediate-period
8
intermediate-period fiber
8
fiber grating
8
environmental disturbances
8
e-hipfg biosensor
8
functionalized e-hipfg
8

Similar Publications

Background: Celiac disease (CeD) has shown an association with autoimmune disorders including vitiligo and alopecia areata (AA). Ritlecitinib, a JAK3 and TEC kinase family inhibitor, has been approved for treatment of patients with AA and is in late-stage development for vitiligo. Ritlecitinib inhibits cytotoxic T cells, NK cells, and B cells which play a role in the pathogenesis of CeD.

View Article and Find Full Text PDF

Evaluation of Complement-Dependent Cytotoxicity Assays for Gene-Edited Pig-to-Human Xenotransplantation.

Xenotransplantation

January 2025

Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Background: Gene-edited pigs for xenotransplantation usually contain one or more transgenes encoding human complement regulatory proteins (CRPs). Because of species differences, human CRP(s) expressed in gene-edited pigs may have difficulty inhibiting the activation of exogenous rabbit complement added to a complement-dependent cytotoxicity (CDC) assay. The use of human complement instead of rabbit complement in CDC experiments may more accurately reflect the actual regulatory activity of human CRP(s).

View Article and Find Full Text PDF

Construction of a Vero cell line expression human KREMEN1 for the development of CVA6 vaccines.

Virol J

January 2025

State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Life Sciences, School of Public Health, Xiamen University, Xiamen, 361102, PR China.

Coxsackievirus A6 (CVA6) has emerged as a major pathogen causing hand, foot and mouth disease (HFMD) outbreaks worldwide. The CVA6 epidemic poses a new challenge in HFMD control since there is currently no vaccine available against CVA6 infections. The Vero cell line has been widely used in vaccine production, particularly in the preparation of viral vaccines, including poliovirus vaccines and EV71 vaccines.

View Article and Find Full Text PDF

Background: Toxoplasma gondii is a ubiquitous parasite that can cause significant complications when it infects pregnant women and immunocompromised patients. These complications include miscarriage, fetal abnormalities, and fatal cerebral toxoplasmosis. Despite its significance, the true burden of toxoplasmosis in Indonesia remains underexplored.

View Article and Find Full Text PDF

The approved intravenous adeno-associated virus (AAV) therapies are limited by the widespread prevalence of pre-existing anti-AAV antibodies in the general population, which are known to restrict patients' ability to receive gene therapy and limit transfection efficacy in vivo. To address this challenge, we have developed a novel recombinant human immunoglobulin G degrading enzyme KJ103, characterized by low immunogenicity and clinical value for the elimination of anti-AAV antibodies in gene transfer. Herein, we conducted two randomized, blinded, placebo-controlled, single ascending dose Phase I studies in China and New Zealand, to evaluate the pharmacokinetics, pharmacodynamics, safety and immunogenicity of KJ103 in healthy volunteers.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!